Can-Fite BioPharma (CANF) Competitors $2.04 -0.11 (-5.12%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrends CANF vs. EQ, ALTS, ACXP, LPCN, LGVN, ITRM, ALGS, NAII, ENLV, and ICCCShould you be buying Can-Fite BioPharma stock or one of its competitors? The main competitors of Can-Fite BioPharma include Equillium (EQ), Janone (ALTS), Acurx Pharmaceuticals (ACXP), Lipocine (LPCN), Longeveron (LGVN), Iterum Therapeutics (ITRM), Aligos Therapeutics (ALGS), Natural Alternatives International (NAII), Enlivex Therapeutics (ENLV), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Can-Fite BioPharma vs. Equillium Janone Acurx Pharmaceuticals Lipocine Longeveron Iterum Therapeutics Aligos Therapeutics Natural Alternatives International Enlivex Therapeutics ImmuCell Equillium (NASDAQ:EQ) and Can-Fite BioPharma (NYSE:CANF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk, community ranking and earnings. Which has more risk & volatility, EQ or CANF? Equillium has a beta of 1.83, indicating that its share price is 83% more volatile than the S&P 500. Comparatively, Can-Fite BioPharma has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Is EQ or CANF more profitable? Can-Fite BioPharma has a net margin of 0.00% compared to Equillium's net margin of -19.51%. Can-Fite BioPharma's return on equity of 0.00% beat Equillium's return on equity.Company Net Margins Return on Equity Return on Assets Equillium-19.51% -36.88% -17.31% Can-Fite BioPharma N/A N/A N/A Which has stronger earnings & valuation, EQ or CANF? Can-Fite BioPharma has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEquillium$36.08M0.81-$13.34M-$0.25-3.32Can-Fite BioPharma$740K9.76-$7.63M-$1.79-1.14 Does the MarketBeat Community prefer EQ or CANF? Equillium received 33 more outperform votes than Can-Fite BioPharma when rated by MarketBeat users. Likewise, 83.72% of users gave Equillium an outperform vote while only 5.36% of users gave Can-Fite BioPharma an outperform vote. CompanyUnderperformOutperformEquilliumOutperform Votes3683.72% Underperform Votes716.28%Can-Fite BioPharmaOutperform Votes35.36%Underperform Votes5394.64% Do analysts rate EQ or CANF? Equillium presently has a consensus target price of $5.00, indicating a potential upside of 502.41%. Can-Fite BioPharma has a consensus target price of $18.00, indicating a potential upside of 782.35%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, analysts clearly believe Can-Fite BioPharma is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Can-Fite BioPharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Do institutionals & insiders have more ownership in EQ or CANF? 27.1% of Equillium shares are held by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are held by institutional investors. 30.3% of Equillium shares are held by insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor EQ or CANF? In the previous week, Equillium had 10 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 11 mentions for Equillium and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 beat Equillium's score of -0.24 indicating that Can-Fite BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Equillium 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Can-Fite BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCan-Fite BioPharma beats Equillium on 10 of the 18 factors compared between the two stocks. Ad Daily Market AlertsInvest in the AI Boom: Top 5 Stocks to WatchBy now, you're well aware of the artificial intelligence boom. Big Tech has been investing billions of dollars into AI, and the market is projected to grow exponentially. According to several recent reports, the AI market, currently valued at around $100 billion, could grow twenty-fold by 2030 to more than $2 trillion. This explosive growth means it's time to consider these top AI stocks. [Click Here to Automatically Download Your Free eBook Now] Get Can-Fite BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CANF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CANF vs. The Competition Export to ExcelMetricCan-Fite BioPharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$7.22M$7.42B$5.54B$19.25BDividend YieldN/A7.96%5.13%3.53%P/E Ratio-1.149.93114.8141.38Price / Sales9.76396.631,495.5514.64Price / CashN/A47.3939.6720.86Price / Book1.165.324.665.39Net Income-$7.63M$153.56M$119.06M$985.39M7 Day Performance-19.37%0.13%0.80%-0.71%1 Month Performance4.08%15.23%5.65%-0.97%1 Year Performance-5.56%41.14%36.75%25.05% Can-Fite BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CANFCan-Fite BioPharma1.4341 of 5 stars$2.04-5.1%$18.00+782.4%-4.2%$7.22M$740,000.00-1.148Analyst DowngradeEQEquillium2.4304 of 5 stars$0.87-36.9%$5.00+474.3%+67.6%$30.84M$42.62M-3.4840Short Interest ↑News CoverageHigh Trading VolumeALTSJanoneN/A$2.44-0.8%N/AN/A$30.72M$2.17M0.00170Short Interest ↑ACXPAcurx Pharmaceuticals1.2429 of 5 stars$1.88-1.1%$12.00+538.3%-63.3%$30.54MN/A-1.623Positive NewsLPCNLipocine1.5794 of 5 stars$5.68+4.8%$10.00+76.1%+137.5%$30.38M$4.80M-3.5710News CoverageLGVNLongeveron3.1085 of 5 stars$2.07-4.2%$8.00+286.5%-90.1%$29.72M$1.23M-0.2420Upcoming EarningsITRMIterum Therapeutics2.8355 of 5 stars$1.29+6.6%$5.00+287.7%+67.1%$29.28MN/A-0.6410Gap UpALGSAligos Therapeutics4.6842 of 5 stars$9.16-6.2%$75.00+718.8%-49.1%$29.28M$7.97M-0.4590Upcoming EarningsHigh Trading VolumeNAIINatural Alternatives International1.0223 of 5 stars$4.57-1.9%N/A-24.4%$28.33M$113.80M-3.72290Analyst ForecastENLVEnlivex Therapeutics3.4122 of 5 stars$1.31-5.1%$6.00+358.0%+2.4%$28.04MN/A-1.1170News CoverageICCCImmuCell0.6704 of 5 stars$3.56-3.0%N/A-29.9%$27.81M$23.22M-6.7275Positive News Related Companies and Tools Related Companies Equillium Alternatives Janone Alternatives Acurx Pharmaceuticals Alternatives Lipocine Alternatives Longeveron Alternatives Iterum Therapeutics Alternatives Aligos Therapeutics Alternatives Natural Alternatives International Alternatives Enlivex Therapeutics Alternatives ImmuCell Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CANF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Can-Fite BioPharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Can-Fite BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
